ClinicalTrials.gg
CompletedNCT01838876Updated Aug 21, 2019Results posted

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

A Phase 3 interventional study of Cariprazine and Antidepressant Therapy (ADT) in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 90 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
442
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Enrollment
26th of 53
442 · median 442
Started
2013
with 1 other
Phase 3
31 of 53
none open now
Registered
26th of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 26th largest by enrollment, is one of 2 that started in 2013, is one of 31 in phase 3, and was the 26th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • MDD
  • Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have provided consent prior to any study specific procedures
  • Meets the , 4th Edition, Text Revision (DSM-IV-TR) criteria for MDD
  • New patients must have ongoing inadequate response to protocol allowed ADTs as reported in Antidepressant Treatment Response Questionnaire (ATRQ)
  • For rollover patients from RGH-MD-72 [NCT01715805], completion of Study RGH-MD-72 (either double-blind or single-blind treatment periods) with continued ADT treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not meet the criteria for MDD.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
442 participants (actual)

Study arms

  • Experimental
    Cariprazine + ADT

    Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.

    Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)

Interventions

  • Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.

  • DrugAntidepressant Therapy (ADT)

    ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.

    Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period and within 30 days of last dose of study drug for participants who did not participate in the 2-week Safety Follow-up Period (Up to 30 weeks)

  2. Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A NEAE is a new AE that occurred during the 2-week Safety Follow-up Period.

    Time frame: 2 weeks following the 26-week Treatment Period

  3. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters

    Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.

    Time frame: Baseline (Week 0) to up to 26 weeks in the Treatment Period

  4. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters

    Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.

    Time frame: Baseline (Week 0) to up to 26 weeks in the Treatment Period plus a 2-week Safety Follow-up Period (Up to 28 weeks)

  5. Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)

    A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.

    Time frame: Baseline (Week 0) to up to 26 weeks

  6. Number of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs

    Extrapyramidal symptoms are drug-induced movement disorders such as dystonia, akathisia, parkinsonism, bradykinesia, tremor, and tardive dyskinesia.

    Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks)

  7. Number of Participants in the Most Severe Suicidal Ideation and Suicidal Behavior Recorded on the C-SSRS During the Treatment Period

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). The C-SSRS also captures information about the intensity of ideation, specifically the frequency, duration, controllability, deterrents, and reasons for the most severe types of ideation. Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior to 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes.

    Time frame: Baseline (Lead-in study Baseline for roll-over participants and prior to first dose in this study for new participants) to Week 26 in this study

  8. Number of Participants With Treatment-Emergent Ocular Events

    A TEAE is an AE that occurs or worsens after receiving study drug. Ocular events are adverse events related to the eye.

    Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks)

  9. Change From Baseline in the Arizona Sexual Experiences Scale (ASEX) Score

    The ASEX is a participant-completed scale to evaluate overall sexual experiences over the previous 7 days consisting of 5 questions answered on a scale of 1 (best) to 6 (worst) for a total possible score of 3 to 30 (2 questions were only answered if the participant was sexually active in the past week), higher score indicates greater sexual dysfunction. There are different forms for males and females. A negative change from Baseline indicates improvement.

    Time frame: Baseline (Lead-in study Baseline for roll-over participants and prior to first dose of this study for new participants) to End of Treatment (Up to Week 26) in this study

07

Results

Posted Aug 21, 2019

Participant flow

Participant flow — Overall Study
MilestoneCariprazine + ADT
Started442
Safety population; received study drug345
Entered safety follow-up period287
Completed209
Not completed233
Withdrew: Adverse event49
Withdrew: Insufficient therapeutic response10
Withdrew: Protocol violation34
Withdrew: Withdrawal of consent33
Withdrew: Lost to follow-up21
Withdrew: Study or site terminated by sponsor1
Withdrew: Reason not specified7
Withdrew: Did not meet eligibility criteria78

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.

Time frame:
First dose of study drug to last dose of study drug in the 26-week Treatment Period and within 30 days of last dose of study drug for participants who did not participate in the 2-week Safety Follow-up Period (Up to 30 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period
ParticipantsCariprazine + ADT
Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period274
PrimaryNumber of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A NEAE is a new AE that occurred during the 2-week Safety Follow-up Period.

Time frame:
2 weeks following the 26-week Treatment Period
Reported as:
Count of participants · Participants
Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period
ParticipantsCariprazine + ADT
Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period20
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters

Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.

Time frame:
Baseline (Week 0) to up to 26 weeks in the Treatment Period
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
ParticipantsCariprazine + ADT
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters0
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters

Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.

Time frame:
Baseline (Week 0) to up to 26 weeks in the Treatment Period plus a 2-week Safety Follow-up Period (Up to 28 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
ParticipantsCariprazine + ADT
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters0
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)

A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.

Time frame:
Baseline (Week 0) to up to 26 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
ParticipantsCariprazine + ADT
Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)1
PrimaryNumber of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs

Extrapyramidal symptoms are drug-induced movement disorders such as dystonia, akathisia, parkinsonism, bradykinesia, tremor, and tardive dyskinesia.

Time frame:
First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs
ParticipantsCariprazine + ADT
Number of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs98
PrimaryNumber of Participants in the Most Severe Suicidal Ideation and Suicidal Behavior Recorded on the C-SSRS During the Treatment Period

The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). The C-SSRS also captures information about the intensity of ideation, specifically the frequency, duration, controllability, deterrents, and reasons for the most severe types of ideation. Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior to 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes.

Time frame:
Baseline (Lead-in study Baseline for roll-over participants and prior to first dose in this study for new participants) to Week 26 in this study
Reported as:
Number · participants
Number of Participants in the Most Severe Suicidal Ideation and Suicidal Behavior Recorded on the C-SSRS During the Treatment Period
participantsCariprazine + ADT
No Suicidal Ideation308
Suicidal Ideation37
Suicidal Ideation with Specific Plan and Intent1
Ideation,Some Intent to Act,without Specific Plan0
Ideation,any Methods,without Intent to Act6
Non-specific Active Suicidal Thoughts3
Wish to be Dead27
No Suicidal Behavior344
Suicidal Behavior1
Completed Suicide0
Actual Suicide Attempt1
PrimaryNumber of Participants With Treatment-Emergent Ocular Events

A TEAE is an AE that occurs or worsens after receiving study drug. Ocular events are adverse events related to the eye.

Time frame:
First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Ocular Events
ParticipantsCariprazine + ADT
Number of Participants With Treatment-Emergent Ocular Events1
PrimaryChange From Baseline in the Arizona Sexual Experiences Scale (ASEX) Score

The ASEX is a participant-completed scale to evaluate overall sexual experiences over the previous 7 days consisting of 5 questions answered on a scale of 1 (best) to 6 (worst) for a total possible score of 3 to 30 (2 questions were only answered if the participant was sexually active in the past week), higher score indicates greater sexual dysfunction. There are different forms for males and females. A negative change from Baseline indicates improvement.

Time frame:
Baseline (Lead-in study Baseline for roll-over participants and prior to first dose of this study for new participants) to End of Treatment (Up to Week 26) in this study
Reported as:
Mean · score on a scale
Change From Baseline in the Arizona Sexual Experiences Scale (ASEX) Score
score on a scaleCariprazine + ADT (Female)Cariprazine + ADT (Male)
Baseline20.1 ± 5.917.2 ± 5.5
Change from Baseline to the End of Treatment-0.9 ± 4.4-0.1 ± 4.6

Adverse events

Collected over First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine + ADT2/345 (0.6%)7/345 (2%)274/345 (79.4%)
Most frequent serious events
Most frequent serious events
EventCariprazine + ADT
Blood creatine phosphokinase increasedInvestigations1/345
Completed suicidePsychiatric disorders1/345
FallInjury, poisoning and procedural complications1/345
PneumoniaInfections and infestations1/345
Road traffic accidentInjury, poisoning and procedural complications1/345
Spinal cord injuryInjury, poisoning and procedural complications1/345
Substance-induced psychotic disorderPsychiatric disorders1/345
Suicide attemptPsychiatric disorders1/345
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCariprazine + ADT
AkathisiaNervous system disorders55/345
HeadacheNervous system disorders40/345
Weight increasedInvestigations34/345
AnxietyPsychiatric disorders34/345
InsomniaPsychiatric disorders34/345
RestlessnessPsychiatric disorders34/345
FatigueGeneral disorders30/345
NasopharyngitisInfections and infestations30/345
NauseaGastrointestinal disorders21/345
DizzinessNervous system disorders20/345

Baseline characteristics

Safety Population included all participants in the enrolled population who took at least 1 dose of cariprazine in this study.

Age, Continuous
Age, Continuous(years)Cariprazine + ADT
Mean46.7 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Cariprazine + ADT
Female249
Male96
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cariprazine + ADT
Race — White280
Race — Black or African American54
Race — Asian6
Race — American Indian or Alaska Native1
Race — Native Hawaiian or Other Pacific Islander1
Race — Other3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cariprazine + ADT
Ethnicity — Hispanic or Latino75
Ethnicity — Non-Hispanic or Latino270
08

Study locations

90 sites
  • Forest Investigative Site 032
    Tucson, Arizona 85710, United States
  • Forest Investigative Site 109
    Tucson, Arizona 85724, United States
  • Forest Investigative Site 105
    Fayetteville, Arkansas 72703, United States
  • Forest Investigative Site 018
    Little Rock, Arkansas 72211, United States
  • Forest Investigative Site 029
    Little Rock, Arkansas 72211, United States
  • Forest Investigative Site 082
    Garden Grove, California 92845, United States
  • Forest Investigative Site 107
    Long Beach, California 90822, United States
  • Forest Investigative Site 104
    National City, California 91950, United States
  • Forest Investigative Site 022
    Newport Beach, California 92660, United States
  • Forest Investigative Site 004
    Oceanside, California 92056, United States
  • Forest Investigative Site 078
    Rancho Mirage, California 92270, United States
  • Forest Investigative Site 080
    Redlands, California 92374, United States
  • Forest Investigative Site 113
    San Diego, California 92102, United States
  • Forest Investigative Site 054
    San Diego, California 92108, United States
  • Forest Investigative Site 007
    San Diego, California 92123, United States
  • Forest Investigative Site 031
    Temecula, California 92591, United States
  • Forest Investigative Site 048
    Denver, Colorado 80239, United States
  • Forest Investigative Site 114
    Norwich, Connecticut 06360, United States
  • Forest Investigative Site 037
    Coral Springs, Florida 33067, United States
  • Forest Investigative Site 053
    Fort Myers, Florida 33912, United States
  • Forest Investigative Site 023
    Hallandale Beach, Florida 33009, United States
  • Forest Investigative Site 071
    Hialeah, Florida 33012, United States
  • Forest Investigative Site 006
    Leesburg, Florida 34748, United States
  • Forest Investigative Site 112
    Maitland, Florida 32751, United States
  • Forest Investigative Site 026
    Miami, Florida 33145, United States
  • Forest Investigative Site 075
    Miami, Florida 33165, United States
  • Forest Investigative Site 027
    North Miami, Florida 33161, United States
  • Forest Investigative Site 074
    North Miami, Florida 33161, United States
  • Forest Investigative Site 036
    Oakland Park, Florida 33334, United States
  • Forest Investigative Site 051
    Orlando, Florida 32803, United States
  • Forest Investigative Site 044
    South Miami, Florida 33143, United States
  • Forest Investigative Site 008
    Tampa, Florida 33613, United States
  • Forest Investigative Site 019
    Winter Park, Florida 32789, United States
  • Forest Investigative Site 060
    Atlanta, Georgia 30329, United States
  • Forest Investigative Site 024
    Atlanta, Georgia 30331, United States
  • Forest Investigative Site 017
    Marietta, Georgia 30060, United States
  • Forest Investigative Site 047
    Smyrna, Georgia 30080, United States
  • Forest Investigative Site 070
    Chicago, Illinois 60612, United States
  • Forest Investigative Site 013
    Hoffman Estates, Illinois 60169, United States
  • Forest Investigative Site 063
    Libertyville, Illinois 60048, United States
  • Forest Investigative Site 062
    Maywood, Illinois 60153, United States
  • Forest Investigative Site 072
    Naperville, Illinois 60563, United States
  • Forest Investigative Site 010
    Oak Brook, Illinois 60523, United States
  • Forest Investigative Site 068
    Skokie, Illinois 60076, United States
  • Forest Investigative Site 061
    Indianapolis, Indiana 46260, United States
  • Forest Investigative Site 042
    Lafayette, Indiana 47905, United States
  • Forest Investigative Site 065
    Overland Park, Kansas 66211, United States
  • Forest Investigative Site 073
    New Orleans, Louisiana 70115, United States
  • Forest Investigative Site 049
    Gaithersburg, Maryland 20877, United States
  • Forest Investigative Site 077
    Rockville, Maryland 20850, United States
  • Forest Investigative Site 110
    Rockville, Maryland 20852, United States
  • Forest Investigative Site 046
    Boston, Massachusetts 02131, United States
  • Forest Investigative Site 045
    Natick, Massachusetts 01760, United States
  • Forest Investigative Site 103
    Saint Charles, Missouri 63304, United States
  • Forest Investigative Site 106
    Berlin, New Jersey 08009, United States
  • Forest Investigative Site 014
    Toms River, New Jersey 08755, United States
  • Forest Investigative Site 058
    Albuquerque, New Mexico 87109, United States
  • Forest Investigative Site 076
    Bronx, New York 10467, United States
  • Forest Investigative Site 028
    Brooklyn, New York 11214, United States
  • Forest Investigative Site 016
    New York, New York 10023, United States
  • Forest Investigative Site 025
    Staten Island, New York 10305, United States
  • Forest Investigative Site 050
    Durham, North Carolina 27710, United States
  • Forest Investigative Site 067
    Bismarck, North Dakota 58501, United States
  • Forest Investigative Site 011
    Cincinnati, Ohio 45219, United States
  • Forest Investigative Site 015
    Cincinnati, Ohio 45227, United States
  • Forest Investigative Site 055
    Columbus, Ohio 43210, United States
  • Forest Investigative Site 066
    Mason, Ohio 45040, United States
  • Forest Investigative Site 064
    Middleburg Heights, Ohio 44130, United States
  • Forest Investigative Site 038
    Oklahoma City, Oklahoma 72112, United States
  • Forest Investigative Site 035
    Oklahoma City, Oklahoma 73103, United States
  • Forest Investigative Site 039
    Oklahoma City, Oklahoma 73112, United States
  • Forest Investigative Site 003
    Portland, Oregon 97210, United States
  • Forest Investigative Site 052
    Allentown, Pennsylvania 18104, United States
  • Forest Investigative Site 102
    Norristown, Pennsylvania 19403, United States
  • Forest Investigative Site 059
    Lincoln, Rhode Island 02865, United States
  • Forest Investigative Site 001
    Charleston, South Carolina 29425, United States
  • Forest Investigative Site 079
    Austin, Texas 78732, United States
  • Forest Investigative Site 005
    Houston, Texas 77008, United States
  • Forest Investigative Site 108
    The Woodlands, Texas 77381, United States
  • Forest Investigative Site 069
    Wichita Falls, Texas 76309, United States
  • Forest Investigative Site 111
    Murray, Utah 84123, United States
  • Forest Investigative Site 041
    Charlottesville, Virginia 22903, United States
  • Forest Investigative Site 081
    Bellevue, Washington 98007, United States
  • Forest Investigative Site 100
    Bothell, Washington 98011, United States
  • Forest Investigative Site 043
    Seattle, Washington 98104, United States
  • Forest Investigative Site 101
    Middleton, Wisconsin 53562, United States
  • Forest Investigative Site 056
    Milwaukee, Wisconsin 53227, United States
  • Forest Investigative Site 057
    Waukesha, Wisconsin 53188, United States
  • Forest Investigative Site 033
    San Juan, 00918, Puerto Rico
  • Forest Investigative Site 034
    San Juan, 00927, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Jul 2015, 26 months.

Results were first posted in Aug 2019, 4 years after primary completion. A results delay was requested in Aug 2016.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 26 months is close to that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2013
First posted
Apr 24, 2013
StartActual
Apr 29, 2013
Primary completionActual
Jul 27, 2015
CompletionActual
Jul 27, 2015
Results delay requested
Aug 2, 2016
Results first posted
Aug 21, 2019
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01838876
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2013
Start date
Apr 29, 2013
Primary completion
Jul 27, 2015
Completion
Jul 27, 2015
Results posted
Aug 21, 2019
Last update
Aug 21, 2019

Study contacts

Willie Earley, MD
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion